Your session is about to expire
← Back to Search
Ribociclib + NSAI/tamoxifen + goserelin for Breast Cancer (MONALEESA-7 Trial)
MONALEESA-7 Trial Summary
This trial will compare the effects of Ribociclib to placebo in premenopausal women with HR positive, HER2 negative advanced breast cancer.
- Breast Cancer (Metastatic)
MONALEESA-7 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMONALEESA-7 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MONALEESA-7 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
At present, how many individuals are enrolled in this research project?
"This particular trial is no longer enrolling patients, as the last update was on September 30th, 2022. However, there are 2368 other trials for malignant neoplasms and 301 for LEE011 that are still admitting participants."
Why is LEE011 given to patients so often?
"LEE011 can be used as a treatment for stage t2b carcinoma of the prostate, ovarian cancer, and other malignant neoplasms."
Are there other examples of LEE011's efficacy?
"LEE011 is being trialled in 301 studies globally, with 89 of those trials being in the final stages. Many of these tests are taking place in Shanghai, but there are 20402 clinical locations running LEE011 trials."
Does this test welcome elderly participants?
"In order to meet the requirements for this study, potential patients must fall between 18 to 59 years old. There are a total 84 trials for patients under 18 and 2548 for people 65 and older."
Has the Food and Drug Administration given LEE011 their seal of approval?
"LEE011 has undergone extensive safety testing and has been determined to be safe for human use."
Share this study with friends
Copy Link
Messenger